Evidence map›Paper›PMID 40375343›Full record

ArticleCardio-oncology (London, England)2025

Impact of hospital variation in hematologic malignancy patient proportions on outcomes of chronic lymphocytic leukemia patients undergoing cardiac surgery: insights from nationwide data analysis.

Meizhen Yi, Lanxin Hu, Jifang Zhou, Yali Ge, Cunhua Su, Fan Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Meizhen Yi *School of International Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Lanxin Hu *Department of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Jifang ZhouSchool of International Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Yali GeDepartment of Anesthesiology, Perioperative and Pain Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. ge_yl@163.com.
Cunhua SuDepartment of Thoracic and Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China. suteensu@163.com.
Fan YangSchool of Science, China Pharmaceutical University, Nanjing, Jiangsu, China. yf@cpu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to investigate the impact of the proportion of hematologic malignancy patients in hospitals on the prognosis of chronic lymphocytic leukemia (CLL) patients undergoing cardiac surgery. Perioperative management of CLL patients is complex, particularly regarding immunosuppression and infection risks.

methodsThis retrospective study utilized data from the National Inpatient Sample (NIS) from 2010 to 2021. Adult CLL patients undergoing cardiac surgery were included, categorizing hospitals into five quintiles based on hematologic malignancy patient proportions. Outcomes included in-hospital mortality, acute kidney injury (AKI), postoperative bleeding, and infections.

resultsAKI incidence was significantly lower in the Q5 group (OR: 0.68, 95% CI: 0.49-0.97), as was the rate of respiratory failure (OR: 0.53, 95% CI: 0.35-0.79). However, the rates of transfusion and acute heart failure were significantly higher in Q5 (acute heart failure OR: 1.70, 95% CI: 1.07-2.77). No significant differences were found in in-hospital mortality or other complications.

conclusionThe proportion of hematologic malignancy patients affects CLL patient outcomes, with higher proportions linked to lower AKI and respiratory failure rates but increased transfusion and heart failure risks. Further research is warranted.

Indexed as

Cardiac surgeryChronic lymphocytic leukemiaClinical complicationsHematologic malignancyNIS databasePrognosis

Identifiers

PMID40375343
PMCPMC12079888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.